RobertoPiliMD

Genitourinary Oncology, Hematologic Oncology

Robert Wallace Miller Professor of Oncology Professor of Medicine Professor of Urology Adjunct Professor of Pharmacology & Toxicology Robert Wallace Miller Professor of Oncology

Join to view full profile

Dr. Pili is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Pili's full profile

Already have an account?

Office
550 University Blvd
Indianapolis, IN 46202
Phone+1 217-274-5000

Fax+1 317-274-5645
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1994 - 1997
University of Cattolica del Sacro CuoreClass of 1989

Certifications & Licensure

NY State Medical License 2009 - 2024
IN State Medical License 2015 - 2021
MD State Medical License 1997 - 2011

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 2
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas Start of enrollment: 2004 Oct 01
Completed
Phase 1
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer Start of enrollment: 2005 May 01
Completed
Phase 2
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Efficacy Study of ABR-215050 to Treat Prostate Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2010 Feb 06
Completed
Phase 1
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery Start of enrollment: 2010 Apr 01
Terminated
Not Applicable
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2012 Feb 01
Terminated
Phase 1
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate Start of enrollment: 2010 Mar 01
Terminated
Phase 1, Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2015 Jan 01
Completed
Phase 2
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Jun 29
Suspended
Phase 1, Phase 2
Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer Start of enrollment: 2017 Dec 19
Completed
Not Applicable
High Dose IL 2 and Entinostat in RCC Start of enrollment: 2018 May 24
Active, not recruiting
Phase 2
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Start of enrollment: 2018 Aug 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, Ilaria Delle Fontane, Li Shen, Sabrina Orsi, Angela J Klunk, W Marston Linehan, Kirk A Staschke, Peter C Hollen...> ;Cancer Research. 2024 Apr 15
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Channing J Paller, Pedro C Barata, Justin Lorentz, Leonard J Appleman, Andrew J Armstrong, Tiffani A DeMarco, Robert Dreicer, Jo Ann B Elrod, Mark Fleming, Christopher...> ;The Prostate. 2024 Feb 1
1 citations
Characteristics and predictors associated with cancer-related fatigue among solid and liquid tumors.
Poolakkad S Satheeshkumar, Roberto Pili, Joel B Epstein, Sudheer B Kurunthatil Thazhe, Rhine Sukumar, Minu Ponnamma Mohan> ;Journal of Cancer Research and Clinical Oncology. 2023 Nov 1
2 citations
Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models.
Christofer Rupert, Carmela Dell' Aversana, Laura Mosca, Vittorino Montanaro, Davide Arcaniolo, Marco De Sio, Antonio Bilancio, Lucia Altucci, Wulf Palinski, Roberto Pi...> ;Journal of Experimental & Clinical Cancer Research. 2023 May 26
5 citations
Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation.
Marco Hadisurya, Zheng-Chi Lee, Zhuojun Luo, Guiyuan Zhang, Yajie Ding, Hao Zhang, Anton B Iliuk, Roberto Pili, Ronald S Boris, W Andy Tao> ;Molecular & Cellular Proteomics. 2023 May 1
A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Steen Knudsen, Anker Hansen, Marie Foegh, Steen Petersen, Hana Mekonnen, Lin Jia, Preeti Shah, Victoria Martin, Gregory Frykman, Roberto Pili> ;Plos One. 2023 Jan 1
1 citations
Relations of perceived injustice to psycho-spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making.
Ekin Secinti, Wei Wu, Ellen F Krueger, Adam T Hirsh, Alexia M Torke, Nasser H Hanna, Nabil Adra, Gregory A Durm, Lawrence Einhorn, Roberto Pili, Shadia I Jalal, Cather...> ;Psycho-Oncology. 2022 Dec 1
10 citations
GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis.
Ricardo A Cordova, Jagannath Misra, Parth H Amin, Anglea J Klunk, Nur P Damayanti, Kenneth R Carlson, Andrew J Elmendorf, Hyeong-Geug Kim, Emily T Mirek, Bennet D Elze...> ;Elife. 2022 Sep 15
Gene expression profiles and treatments for metastatic renal cell carcinoma: What does still need to be defined?
Emilio F Giunta, Pasquale Rescigno, Roberto Pili> ;Asian Journal of Urology. 2022 Jul 1
6 citations
Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.
Xuedan He, Shiqi Zhou, Melissa Dolan, Yuhao Shi, Jianxin Wang, Breandan Quinn, Dushyant Jahagirdar, Wei-Chiao Huang, Moriya Tsuji, Roberto Pili, Fumito Ito, Joaquin Or...> ;Journal for Immunotherapy of Cancer. 2021 Dec 1
COVID-19 and the excess of mortality in Italy from January to April 2020: what are the risks for oldest old?
Eraldo Francesco Nicotra, Roberto Pili, Luca Gaviano, Gian Pietro Carrogu, Roberta Berti, Paola Grassi, Donatella Rita Petretto> ;Journal of Public Health Research. 2021 Sep 20
Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer’s Clinical Notes
Donatella Rita Petretto, Gian Pietro Carrogu, Luca Gaviano, Lorenzo Pili, Roberto Pili> ;Geriatrics. 2021 Jan 11
7 citations
Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
Rachel A. Caston, Fenil Shah, Colton L. Starcher, Randall Wireman, Olivia Babb, Michelle Grimard, Jack McGeown, Lee Armstrong, Yan Tong, Roberto Pili, Joseph E. Rupert...> ;Journal of Cellular and Molecular Medicine. 2021 Jan 1
14 citations
Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
Elena Beketova, Shuyi Fang, Jake L. Owens, Sheng Liu, Xufeng Chen, Qingfu Zhang, Andrew M. Asberry, Xuehong Deng, Jonathan Malola, Jiaoti Huang, Chenglong Li, Roberto ...> ;Cancer Research. 2020 Nov 15
49 citations
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Martin H. Voss, Michael S. Gordon, Monica M. Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David Smith, Andrés Cervantes, Igor Puzanov, Roberto Pili, Ding Wang,...> ;British Journal of Cancer. 2020 Sep 11
3 citations
Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions.
Austin Goldsamt, Nur P. Damayanti, Filomena de Nigris, Roberto Pili> ;Cancer Journal. 2020 Sep 1
10 citations
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carci...
Anthony C. Wood, Saby George, Nabil Adra, Sreenivasulu Chintala, Nur P. Damayanti, Roberto Pili> ;Investigational New Drugs. 2020 Aug 1
8 citations
The combination of low skeletal muscle mass and high tumor interleukin-6 associates with decreased survival in clear cell renal cell carcinoma
Joshua K. Kays, Leonidas G. Koniaris, Caleb A. Cooper, Roberto Pili, Guanglong Jiang, Yunlong Liu, Teresa A. Zimmers> ;Cancers. 2020 Jun 17
2 citations
Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer
Josephine F. Trott, Omran Abu Aboud, Bridget McLaughlin, Katie L. Anderson, Jaime F. Modiano, Kyoungmi Kim, Kuang-Yu Jen, William Senapedis, Hua Chang, Yosef Landesman...> ;Kidney360. 2020 May 28
60 citations
Ageing and COVID-19: What is the Role for Elderly People?
Donatella Rita Petretto, Roberto Pili> ;Geriatrics. 2020 Apr 26
126 citations
CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors
Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L. Maughan, Roberto Pili, Nabil Adra, Cora N. Stern...> ;JCO Precision Oncology. 2020 Apr 21
29 citations
Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy.
Hayley C. Affronti, Aryn M. Rowsam, Anthony J. Pellerite, Spencer Rosario, Mark D. Long, Justine J. Jacobi, Anna Bianchi-Smiraglia, Christoph S. Boerlin, Bryan Gillard...> ;Nature Communications. 2020 Jan 7
10 citations
Dual inhibition of angiopoietin-Tie2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma
May Elbanna, Ashley Orillion, Nur P. Damayanti, Remi Adelaiye-Ogala, Li Shen, Kiersten Marie Miles, Sreenivasulu Chintala, Eric Ciamporcero, Swathi Ramakrishnan, Sheng...> ;Molecular Cancer Therapeutics. 2020 Jan 1
26 citations
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer.
Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z. Kaimakliotis, George E. Sandusky, Chi Zhang, Roberto Pili, Mark ...> ;Molecular Cancer Therapeutics. 2019 Nov 1
4 citations
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
M. Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, Russell Z. Szmulewitz, Thomas Powles, Roberto Pili, Justine Yang Bruce, Ulka N. Vaishampayan, James Larkin, Brad Rosb...> ;The Oncologist. 2019 Sep 1
Join now to see all

Journal Articles

Phase 1 Trials of Anti-ENPP3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Roberto Pili, John A Thompson, Clinical Cancer Research
Dietary Protein Restriction Reprograms Tumor Associated Macrophages and Enhances Immunotherapy
Roberto Pili, MD, Clinical Cancer Research

Lectures

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.
2019 ASCO Annual Meeting - 6/1/2019

Other

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Roberto Pili, MD, Clinical Cancer Research
https://www.doximity.com/articles/8af396e1-337c-4e92-bdbb-e87959af489d
UpToDate, Wolters Kluwer Health - 2013-04-10

Authored Content

Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018

Press Mentions

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.March 27th, 2023
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.June 15th, 2022
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.June 15th, 2022
Join now to see all